The Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillance

Overview

Journal Pathogens

Date 2023 Nov 25

PMID 38003824

Authors

Francisco Llorente

Elisa Perez-Ramirez

Mayte Perez-Olmeda

Desiree Dafouz-Bustos

Jovita Fernandez-Pinero

Mercedes Martinez-Cortes

Miguel Angel Jimenez-Clavero

Affiliations

Soon will be listed here.

Abstract

The presence of SARS-CoV-2 antibodies was examined over 7 months in a population of essential service workers exposed during the first epidemic wave in Madrid (Spain). Results obtained with different serological assays were compared. Firstly, serum samples obtained in April 2020 were analyzed using eleven SARS-CoV-2 antibody detection methods, including seven ELISAs, two CLIAs and two LFAs. While all of the ELISA tests and the Roche eCLIA method showed good performance, it was poorer for the Abbott CLIA and LFA tests. Sera from 115 workers with serologically positive results in April were collected 2 and 7 months after the first sampling and were analyzed using five of the tests previously assessed. The results showed that while some ELISA tests consistently detected the presence of anti-SARS-CoV-2 antibodies even 7 months after first detection, other methods, such as the Abbott CLIA test, showed an important reduction in sensitivity for these mature antibodies. The sensitivity increased after establishing new cut-off values, calculated taking into account both recent and old infections, suggesting that an adjustment of assay parameters may improve the detection of individuals exposed to the infection.

References

Mylemans M, Van Honacker E, Nevejan L, Van Den Bremt S, Hofman L, Poels J . Diagnostic and analytical performance evaluation of ten commercial assays for detecting SARS-CoV-2 humoral immune response. J Immunol Methods. 2021; 493:113043. PMC: 7989098. DOI: 10.1016/j.jim.2021.113043. View

Zedan H, Yassine H, Al-Sadeq D, Liu N, Qotba H, Nicolai E . Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies. Sci Rep. 2022; 12(1):19020. PMC: 9643483. DOI: 10.1038/s41598-022-21317-x. View

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

Martinez-Cortes M, Leon-Dominguez C, Fernandez-Pinero J, Rodriguez M, Almonacid M, Ferrari M . SARS-CoV-2 surveillance strategy in essential workers of the Madrid City Council during the first epidemic wave in Spain, March-July 2020. Occup Environ Med. 2021; 79(5):295-303. DOI: 10.1136/oemed-2021-107654. View

Favresse J, Eucher C, Elsen M, Gillot C, Van Eeckhoudt S, Dogne J . Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms. 2021; 9(3). PMC: 8001517. DOI: 10.3390/microorganisms9030556. View

Mendez-Echevarria A, Sainz T, Falces-Romero I, De Felipe B, Escolano L, Alcolea S . Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population. Pathogens. 2021; 10(6). PMC: 8226775. DOI: 10.3390/pathogens10060700. View

Lopez M, Chiner-Oms A, Garcia de Viedma D, Ruiz-Rodriguez P, Bracho M, Cancino-Munoz I . The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nat Genet. 2021; 53(10):1405-1414. PMC: 8481935. DOI: 10.1038/s41588-021-00936-6. View

Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M . Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021; 71:103561. PMC: 8390300. DOI: 10.1016/j.ebiom.2021.103561. View

Perez-Saez J, Zaballa M, Yerly S, Andrey D, Meyer B, Eckerle I . Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021; 27(11):1695.e7-1695.e12. PMC: 8261139. DOI: 10.1016/j.cmi.2021.06.040. View

10.

Gong F, Wei H, Li Q, Liu L, Li B . Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis. Front Mol Biosci. 2021; 8:682405. PMC: 8343015. DOI: 10.3389/fmolb.2021.682405. View

11.

Zhang Y, Huang Z, Zhu J, Li C, Fang Z, Chen K . An updated review of SARS-CoV-2 detection methods in the context of a novel coronavirus pandemic. Bioeng Transl Med. 2022; :e10356. PMC: 9349698. DOI: 10.1002/btm2.10356. View

12.

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

13.

Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan M, Perez-Olmeda M . Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396(10250):535-544. PMC: 7336131. DOI: 10.1016/S0140-6736(20)31483-5. View

14.

Williams L, Jurado S, Llorente F, Romualdo A, Gonzalez S, Saconne A . The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests. Front Plant Sci. 2021; 12:699665. PMC: 8354202. DOI: 10.3389/fpls.2021.699665. View

15.

Jugwanth S, Gededzha M, Mampeule N, Zwane N, David A, Burgers W . Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442. PMC: 8815965. DOI: 10.1371/journal.pone.0262442. View

16.

van den Beld M, Murk J, Kluytmans J, Koopmans M, Reimerink J, van Loo I . Increasing the Efficiency of a National Laboratory Response to COVID-19: a Nationwide Multicenter Evaluation of 47 Commercial SARS-CoV-2 Immunoassays by 41 Laboratories. J Clin Microbiol. 2021; 59(9):e0076721. PMC: 8373020. DOI: 10.1128/JCM.00767-21. View

17.

Stefanelli P, Bella A, Fedele G, Pancheri S, Leone P, Vacca P . Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clin Microbiol Infect. 2020; 27(4):633.e1-633.e7. PMC: 7695553. DOI: 10.1016/j.cmi.2020.11.013. View

18.

Dortet L, Ronat J, Vauloup-Fellous C, Langendorf C, Mendels D, Emeraud C . Evaluating 10 Commercially Available SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) Method. J Clin Microbiol. 2020; 59(2). PMC: 8111137. DOI: 10.1128/JCM.02342-20. View

19.

Parai D, Dash G, Choudhary H, Peter A, Rout U, Nanda R . Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies. J Virol Methods. 2021; 292:114121. PMC: 7934617. DOI: 10.1016/j.jviromet.2021.114121. View

20.

Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J . Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Front Immunol. 2022; 13:829665. PMC: 8828498. DOI: 10.3389/fimmu.2022.829665. View